

- , 2009 2/4

(2009 7 30 - ) - 2009 2/4 7 29

1. 2009 2/4

- 2009 2/4 (net sales) +11.2% 74 3800  
( 13 691 )
- (net income) 22 6800 ( 3 9850 ) +29.4% 가 .
- (EPS) 1.74 ( 3057 ) +29.9% .
- 2009 2/4 <sup>®</sup>(+26.0%), <sup>®</sup> (+13.3%), <sup>®</sup> (+10.7%),  
(+18.4%), (+9.6%) (+5.4%), (+4.6%)  
(+20.1%) ( )
- 2009 7 1 FDA <sup>®</sup> 7 28

2. 2009

- +6.7% 가 145 4500 ( 25 5567 )
- 2009 44 4600 ( 7 8119 )
- +22.3%
- (EPS) 3.41 ( 5991 ) +23.1%

3. (Transformation)

- R&D 가 : (triple negative breast cancer) BSI-  
201 가 3 , (Exelixis)社
- : (Shantha Biotechnics)社 (Zentiva), (Medley),  
(Kendrick)社 3
- CEO (Chris Viehbacher) “ 2/4 ,
- . 7 . 2009  
(EPS) 10% . R&D

- 2013 가

( )  
(1)

(2) (1 =1757.08 ) 가

- (sanofi-aventis)  
100 - (sanofi-aventis) 1  
19,000 29 R&D  
, 7

###